Aquestive Therapeutics shares plunged about 40% premarket after the US Food and Drug Administration said deficiencies currently prevent labeling discussions for Anaphylm, its sublingual epinephrine film. While the FDA said its review is ongoing and no final decision has been made, the setback raised concerns ahead of the January 31 PDUFA date.